Zealand Pharma A/S (CPH:ZEAL)
463.40
-6.20 (-1.32%)
Dec 17, 2025, 2:39 PM CET
Zealand Pharma Employees
Zealand Pharma had 335 employees as of December 31, 2024. The number of employees increased by 82 or 32.41% compared to the previous year.
Employees
335
Change (1Y)
82
Growth (1Y)
32.41%
Revenue / Employee
20.81M DKK
Profits / Employee
14.87M DKK
Market Cap
33.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 335 | 82 | 32.41% |
| Dec 31, 2023 | 253 | 57 | 29.08% |
| Dec 31, 2022 | 196 | -159 | -44.79% |
| Dec 31, 2021 | 355 | 26 | 7.90% |
| Dec 31, 2020 | 329 | 150 | 83.80% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 77,349 |
| Demant | 22,639 |
| Coloplast | 16,744 |
| GN Store Nord | 7,347 |
| H. Lundbeck | 5,707 |
| Ambu A/S | 5,384 |
| Embla Medical | 4,061 |
| ALK-Abelló | 2,753 |
Zealand Pharma News
- 1 day ago - Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript - Seeking Alpha
- 5 days ago - Zealand Pharma A/S (ZLDPF) Analyst/Investor Day - Slideshow - Seeking Alpha
- 5 days ago - Zealand Pharma increases its share capital as a result of the exercise of employee warrants - GlobeNewsWire
- 5 days ago - Zealand Pharma (ZLDPF) Partners with OTR Therapeutics for Metabolic Disease Therapies - GuruFocus
- 6 days ago - Zealand Pharma Unveils Strategy To Lead In Metabolic Health - Nasdaq
- 6 days ago - Zealand Pharma to accelerate drug development for obesity, metabolic disease - Reuters
- 6 days ago - Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health - GlobeNewsWire
- 6 days ago - Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases - GlobeNewsWire